AAD-2004, an experimental drug which claims to treat major neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), may be around the corner.
Developed by the Korean firm Neurotech Pharmaceuticals Co., Ltd, AAD-2004 has both anti-oxidative and anti-inflammatory activities.
AAD-2004 has a dual function reducing free radicals and PGE2. Oxidative stress resulting from free radicals and PGE 2 are considered causing nerve injury in Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.
AAD-2004 prevents the progression of Alzheimer’s by cutting down A-beta. Studies in mice showed that AAD-2004 improved cognition besides anti-oxidant and neuroprotective properties in chronic Alzheimer’s disease.
When treated with AAD-2004, ALS-induced mice demonstrated improved motor function. The drug also showed excellent anti-oxidant, anti-nflammatory and neuroprotective activities in mice suffering from chronic ALS disease.
The drug also showed efficacy as neuroprotective agent in Parkinson’s and epilepsy as acute therapy.
Nerotech has completed preclinical studies of AAD-2004 in UK.
The company has begun dosing studies in the Phase 1 clinical testing of the drug AAD-2004, according to a press release.
The Phase 1 study, which is scheduled to begin in April 2010, will evaluate the safety, tolerability, and pharmacokinetics of AAD-2004 in healthy volunteers.
Two initial clinical studies have been completed without serious adverse events to AAD-2004.
Alzheimer’s is a devastating disease that hinders the patient’s ability to remember, learn, perform daily activities and relate to others.
It is generally very difficult to diagnose Alzheimer’s disease. Doing a postmortem autopsy of the brain is the only way currently available to diagnose the disease.
It is now estimated that every 70 seconds someone develops the condition, according to the Alzheimer’s Association. The association further estimates that about 5.3 million Americans are living with Alzheimer’s.